0.14412.93% ( +0.0041 )
Closed: Nov 13, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -0.37, above the reasonable range, cheaper than 0.54% of the time in the past 5 years, and the industry ranks 148/607, the industry Median -1.72.
-0.368xP/E
$0.14Stock price
$-0.39Earnings per share
-0.368xP/E
Stock price$0.14Earnings per share$-0.39
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.32x
- Typical range
- -3.94x–-1.72x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.98x | 162.77% | $208.48B |
MRNAUSModerna | -31.97x | 1.49% | $89.18B |
CSLLYUSCSL Limited | -25.56x | -- | $65.92B |
NTRAUSNatera | -280.91x | 1.38% | $46.27B |
RVMDUSRevolution Medicines | -19.74x | 40.80% | $36.93B |
ROIVUSRoivant Sciences | -83.18x | 94.91% | $28.64B |
INSMUSInsmed | -43.89x | 74.47% | $26.58B |
BNTXUSBioNTech SE | -12.54x | 29.49% | $21.22B |
BBIOUSBridgebio Pharma | -25.76x | 30.83% | $15.25B |
SMMTUSSummit Therapeutics | -13.56x | 23.12% | $11.29B |
BMRNUSBioMarin Pharma | -579.92x | 56.09% | $11.09B |
KYMRUSKymera Therapeutics | -30.36x | 8.74% | $10.61B |
PCVXUSVaxcyte | -8.73x | 42.58% | $10.03B |
MDGLUSMadrigal Pharma | -63.86x | 86.93% | $9.93B |
SYREUSSpyre Therapeutics | -44.09x | 59.92% | $9.88B |
PRAXUSPraxis Precision Medicines | -25.52x | 0.52% | $9.17B |
RYTMUSRhythm Pharma | -40.21x | 51.65% | $7.97B |
ALKSUSAlkermes | -22,515.92x | 134.09% | $7.90B |
CYTKUSCytokinetics | -10.05x | 8.60% | $7.82B |
TWSTUSTwist Bioscience | -56.43x | 34.96% | $7.35B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
